HOME >> BIOLOGY >> NEWS
Novel therapies show promise against myeloid leukemia

(San Diego, Calif., December 6, 2003) Leukemia, a cancer of the white blood cells, starts in the bone marrow but can spread to the blood, lymph nodes, and other organs. Because of its complexity and varying courses in each patient, the development of new and effective treatments for the disease has been challenging for scientists. According to research presented during the 45th Annual Meeting of the American Society of Hematology, novel therapeutic approaches directed against unique targets provide new hope for those suffering from these diseases.

"While the survival rate for leukemia has improved in the past two decades, especially among children, it is still a very difficult disease to treat in adults," said Richard Larson, M.D., University of Chicago Hospital. "New treatments are beginning to improve survival."

Probability and Impact of Obtaining a Cytogenetic Response to Imatinib as Initial Therapy for Chronic Myeloid Leukemia (CML) in Chronic Phase (Abstract 634)

Chronic myeloid leukemia (CML), a malignant cancer of the bone marrow, is one of the most common forms of leukemia. Imatinib (Gleevec), which blocks the abnormal protein driving the overproduction of abnormal white blood cells, has become the standard therapy for patients not undergoing stem cell transplantation. In newly diagnosed patients, researchers are still uncertain about the length of time imatinib should be administered to adequately determine a response. To assist patients and physicians in weighing the risks and benefits of continuing imatinib, this issue was recently examined by researchers from the Oregon Health & Science University Cancer Institute by analyzing data on 553 newly diagnosed chronic phase patients who were treated intitially with imatinib as part of a multi-national study that compared imatinib to interferon+Ara-C (cytosine arabinoside, the previous standard therapy for CML).

Scientists
'"/>

Contact: Aimee Frank
amf@spectrumscience.com
202-955-6222
American Society of Hematology
6-Dec-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel sensors help clear the air
5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
8. Novel bacterium detoxifies chlorinated pollutants
9. Novel flu vaccine shows promise in mice
10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
11. Novel method identifies hidden genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces ... addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market ... hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS ...
(Date:10/11/2017)... , ... October 11, 2017 , ... Personal eye wash is a basic first aid ... at a time. So which eye do you rinse first if a dangerous substance enters ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its dirt ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives ... the award for Excellence in Volunteer Experience from US2020. , US2020’s mission is ...
Breaking Biology Technology:
Cached News: